NCT06345885已完成4 期
Immunogenicity and Safety of One Dose of Cecolin and One Dose of Gardasil
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Anti-HPV seropositivity
研究概览
简要总结
This study will assess the immunogenicity and safety of one dose of Cecolin and one dose of Gardasil
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 9 Years 至 14 Years（Child）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Female, aged between 9 and 14 years (including 9 and 14 years) on the day of enrollment
- •Judged as healthy and eligible for vaccination by the investigators through a self- reported medical history and some physical examinations
- •Subjects and legal guardians are informed and agree, and sign the Informed Consent Form
- •Female urine pregnancy test is negative
排除标准
- •Axillary temperature>37.2 ℃
- •Other investigational or unregistered products (drugs or vaccines) that have been used or planned to be used during the study period within 30 days prior to receiving the research vaccine
- •Systemic use of immunosuppressants or other immunomodulatory drugs or corticosteroids for a long period of time (lasting for more than 14 days) within 6 months prior to receiving the research vaccine, but local use is allowed (such as ointments, eye drops, inhalers, or nasal sprays)
- •Within 3 months prior to vaccination, immunoglobulin and/or blood preparations were used or planned to be used during the study period, but emergency use of tetanus immunoglobulin and rabies immunoglobulin is allowed after exposure
- •Received inactivated vaccines within 14 days prior to enrollment in the study, or received live vaccines within 21 days prior to enrollment in the study
- •Fever (axillary temperature ≥ 38.0 ℃) within 3 days prior to vaccination, or any acute illness requiring systemic antibiotics or antiviral treatment within the past 5 days
- •Previously received HPV vaccine
- •Immunodeficiency diseases, chronic medical histories that require treatment for important organs such as primary diseases, cancer (or precancerous lesions), immune diseases (including systemic lupus erythematosus, rheumatoid arthritis, any condition leading to splenectomy or splenectomy, and other immune diseases that researchers believe may have an impact on immune response)
- •Have a history of allergies, including serious adverse reactions from previous vaccination, such as allergies, urticaria, breathing difficulties, angiogenic edema, or abdominal pain
- •Asthma, with unstable conditions in the past two years requiring emergency treatment, hospitalization, oral or intravenous corticosteroids
- •Complicated with serious medical diseases, such as hypertension, heart disease, diabetes, hyperthyroidism, etc
- •Abnormal coagulation function (such as coagulation factor deficiency, coagulation disorders, platelet abnormalities) or coagulation disorders diagnosed by doctors
- •Epilepsy, excluding febrile epilepsy under 2 years old and simple epilepsy that did not require treatment in the past 3 years
- •Due to the inability to comply with research requirements due to psychological conditions, having a past or present mental illness that has not been well controlled within the past two years, requiring medication for mental illness, and having suicidal tendencies in the past five years
- •According to the researcher's judgment, due to various medical, psychological, social, occupational factors or other conditions, it is contrary to the research plan or affects the recipient and guardian to sign informed consent
结局指标
主要结局
Anti-HPV seropositivity
时间窗: At 1 month after first dose
Seropositivity to HPV16 and HPV18 types of the neutralizing antibody in subjects will be assessed.
次要结局
- Anti-HPV Seropositivity(At 2 months after first dose)
- Local and Systemic Reactions/Event(7 and 30 days after each dose of vaccination; 0-7 months)
- HPV Antibody Titers(At 1 and 2 months after first dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)Genital WartsCervical CancerNCT00092482Merck Sharp & Dohme LLC3,882
Unknown
2 期
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy AdultsWhooping CoughDiphtheriaTetanusNCT04238975Green Cross Corporation213
已完成
1 期
A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older AdultsRespiratory Syncytial Virus InfectionsNCT03814590GlaxoSmithKline1,053
Unknown
不适用
Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected MenAnal CancerHIV InfectionsNCT00666107Southern California Institute for Research and Education150
已完成
3 期
A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)Healthy Adult Female ParticipantsPreventionPapillomavirus InfectionHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18NCT00090220Merck Sharp & Dohme LLC3,819